Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accounts Payables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accounts Payables for 3 consecutive years, with $355000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 68.33% to $355000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $355000.0, a 68.33% decrease, with the full-year FY2025 number at $355000.0, down 68.33% from a year prior.
  • Accounts Payables was $355000.0 for Q4 2025 at Artiva Biotherapeutics, down from $848000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $2.0 million in Q1 2025 to a low of $355000.0 in Q4 2025.
  • A 3-year average of $1.0 million and a median of $984500.0 in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: skyrocketed 82.57% in 2024, then crashed 68.33% in 2025.
  • Artiva Biotherapeutics' Accounts Payables stood at $614000.0 in 2023, then skyrocketed by 82.57% to $1.1 million in 2024, then plummeted by 68.33% to $355000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Accounts Payables are $355000.0 (Q4 2025), $848000.0 (Q3 2025), and $1.2 million (Q2 2025).